Clinical proteomics and mass spectrometry profiling for cancer detection

Expert Review of Proteomics

Volumn 3, Issue 3, 2006, Pages 311-320

  Solassol, Jérôme ^a   Jacot, William ^a   Lhermitte, Ludovic ^a   Boulle, Nathalie ^a   Maudelonde, Thierry ^a   Mangé, Alain ^a  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

Biomarker; Cancer; Clinical proteomics; Clinprot ; SELDI TOF

Indexed keywords

BIOLOGICAL MARKER;

AFFINITY CHROMATOGRAPHY; CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER SCREENING; CANCER SURVIVAL; DISEASE COURSE; HUMAN; MASS SPECTROMETRY; MEDICAL EXPERT; MEDICAL INSTRUMENTATION; PROTEOMICS; REVIEW; STATISTICAL ANALYSIS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; VALIDATION STUDY;

CHROMATOGRAPHY, AFFINITY; HUMANS; MASS SPECTROMETRY; NEOPLASM PROTEINS; NEOPLASMS; PROTEIN ARRAY ANALYSIS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 33745565779     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.3.3.311     Document Type: Review

References (86)

1. MacNeil JS. Better biomarkers for the diagnostics labyrinth. Genome Technol. 24-33 (2004).
2. Petricoin EF, Liotta LA. SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr. Opin. Biotechnol. 15, 24-30 (2004).
3. Villanueva J, Philip J, Entenberg D et al. Serum peptide profiling by magnetic particleassisted, automated sample processing and MALDI-TOF mass spectrometry. Anal. Chem. 76, 1560-1570 (2004). First description of peptide profiling in serum using Clinprot™.
4. Weissinger EM, Wittke S, Kaiser T et al. Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes. Kidney Int. 65, 2426-2434 (2004).
5. Neuhoff N, Kaiser T, Wittke S et al. Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface-enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry. Rapid Commun. Mass Spectrom. 18, 149-156 (2004).
6. Govorukhina NI, Keizer-Gunnink A, van der Zee AG, de Jong S, de Bruijn HW, Bischoff R. Sample preparation of human serum for the analysis of tumor markers. Comparison of different approaches for albumin and γ-globulin depletion. J. Chromatogr. A 1009, 171-178 (2003).
7. Chaurand P, Schwartz SA, Caprioli RM. Assessing protein patterns in disease using imaging mass spectrometry. J. Proteome Res. 3, 245-252 (2004).
8. Lollo BA, Harvey S, Liao J et al. Improved two-dimensional gel electrophoresis representation of serum proteins by using ProtoClear. Electrophoresis 20, 854-859 (1999).
9. Ahmed N, Barker G, Oliva K et al. An approach to remove albumin for the proteomic analysis of low abundance biomarkers in human serum. Proteomics 3, 1980-1987 (2003).
10. Wang YY, Cheng P, Chan DW. A simple affinity spin tube filter method for removing high-abundant common proteins or enriching low-abundant biomarkers for serum proteomic analysis. Proteomics 3, 243-248 (2003).
11. Solassol J, Marin P, Demettre E et al. Proteomic detection of prostate-specific antigen using a serum fractionation procedure: potential implication for new low-abundance cancer biomarkers detection. Anal. Biochem. 338, 26-31 (2005).
12. Merrell K, Southwick K, Graves SW, Esplin MS, Lewis NE, Thulin CD. Analysis of low-abundance, low-molecular-weight serum proteins using mass spectrometry. J. Biomol. Tech. 15, 238-248 (2004).
13. Linke T, Ross AC, Harrison EH. Profiling of rat plasma by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry, a novel tool for biomarker discovery in nutrition research. J. Chromatogr. A 1043, 65-71 (2004).
14. Chatterjee SJ, Datar R, Youssefzadeh D et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J. Clin. Oncol. 22, 1007-1013 (2004).
15. Petricoin EF, Ardekani AM, Hitt BA et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359, 572-577 (2002). First study using surface-enhanced laser desorption/ionization (SELDI) time-offlight (TOF) profiling, which was presented as a significant improvement in the early detection setting of ovarian carcinoma.
16. Pearl DC. Proteomic patterns in serum and identification of ovarian cancer. Lancet 360, 169-170; author reply 170-171 (2002). Critical report concerning the positive predictive value reported in [15]. Also contains a table of positive predictive values of a hypothetical test depending on prevalence and specificity.
17. Rockhill B. Proteomic patterns in serum and identification of ovarian cancer. Lancet 360, 169; author reply 170-171 (2002). Critical report concerning the positive predictive value reported in [15].
18. Diamandis EP. Proteomic patterns in serum and identification of ovarian cancer. Lancet 360, 170; author reply 170-171 (2002).
19. Conrads TP, Fusaro VA, Ross S et al. High-resolution serum proteomic features for ovarian cancer detection. Endocr. Relat. Cancer 11, 163-178 (2004).
20. Kozak KR, Amneus MW, Pusey SM et al. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc. Natl Acad. Sci. USA 100, 12343-12348 (2003).
21. Adam BL, Qu Y, Davis JW et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 62, 3609-3614 (2002).
22. Villanueva J, Shaffer DR, Philip J et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Invest. 116, 271-284 (2006).
23. Zhang Z, Bast RC Jr, Yu Y et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 64, 5882-5890 (2004). Multicenter study of ovarian cancer with standardized protocols enabling a crossover-independent validation of three serum potential markers.
24. Ye B, Cramer DW, Skates SJ et al. Haptoglobin-α subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin. Cancer Res. 9, 2904-2911 (2003).
25. Rosty C, Christa L, Kuzdzal S et al. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res. 62, 1868-1875 (2002).
26. Vlahou A, Schellhammer PF, Mendrinos S et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am. J. Pathol. 158, 1491-1502 (2001).
27. Paradis V, Degos F, Dargere D et al. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology 41, 40-47 (2005).
28. Hlavaty JJ, Partin AW, Shue MJ et al. Identification and preliminary clinical evaluation of a 50.8-kDa serum marker for prostate cancer. Urology 61, 1261-1265 (2003).
29. Malik G, Ward MD, Gupta SK et al. Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. Clin. Cancer Res. 11, 1073-1085 (2005).
30. Cheng AJ, Chen LC, Chien KY et al. Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. Clin. Chem. 51, 2236-2244 (2005).
31. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J. Natl Cancer Inst. 96, 353-356 (2004).
32. Coussens LM, Werb Z. Inflammation and cancer. Nature 420, 860-867 (2002).
33. Liotta LA, Ferrari M, Petricoin E. Clinical proteomics: written in blood. Nature 425, 905 (2003).
34. Mehta AI, Ross S, Lowenthal MS et al. Biomarker amplification by serum carrier protein binding. Dis. Markers 19, 1-10 (2003).
35. Mok SC, Chao J, Skates S et al. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J. Natl Cancer Inst. 93, 1458-1464 (2001).
36. Matrisian LM, Sledge GW Jr, Mohla S. Extracellular proteolysis and cancer: meeting summary and future directions. Cancer Res. 63, 6105-6109 (2003).
37. Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr. Rev. 22, 184-204 (2001).
38. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol. Cell. Proteomics 3, 367-378 (2004).
39. Baggerly KA, Morris JS, Coombes KR. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 20, 777-785 (2004).
40. Karsan A, Eigl BJ, Flibotte S et al. Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis. Clin. Chem. 51, 1525-1528 (2005).
41. Semmes OJ, Feng Z, Adam BL et al. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin. Chem. 51, 102-112 (2005). First attempt to estimate the cross-laboratory SELDI-TOF reproducibility.
42. Rai AJ, Stemmer PM, Zhang Z et al. Analysis of Human Proteome Organization Plasma Proteome Project (HUPO PPP) reference specimens using surface enhanced laser desorption/ionization-time of flight (SELDI-TOF) mass spectrometry: multi-institution correlation of spectra and identification of biomarkers. Proteomics 5, 3467-3474 (2005).
43. Findeisen P, Sismanidis D, Riedl M, Costina V, Neumaier M. Preanalytical impact of sample handling on proteome profiling experiments with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin. Chem. 51, 2409-2411 (2005).
44. Baumann S, Ceglarek U, Fiedler GM, Lembcke J, Leichtle A, Thiery J. Standardized approach to proteome profiling of human serum based on magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin. Chem. 51, 973-980 (2005).
45. de Noo ME, Tollenaar RA, Ozalp A et al. Reliability of human serum protein profiles generated with C8 magnetic beads assisted MALDI-TOF mass spectrometry. Anal. Chem. 77, 7232-7241 (2005).
46. Petricoin E III, Liotta LA. Counterpoint: the vision for a new diagnostic paradigm. Clin. Chem. 49, 1276-1278 (2003). Controversy concerning the ability to detect low-abundance proteins in serum using mass spectrometry profiling.
47. Diamandis EP. Point: proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin. Chem. 49, 1272-1275 (2003). Controversy concerning the ability to detect low-abundance proteins in serum using mass spectrometry profiling.
48. Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S, Farias-Eisner R. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 5, 4589-4596 (2005).
49. Moshkovskii SA, Serebryakova MV, Kuteykin-Teplyakov KB et al. Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1. Proteomics 5, 3790-3797 (2005).
50. Petricoin EF III, Ornstein DK, Paweletz CP et al. Serum proteomic patterns for detection of prostate cancer. J. Natl Cancer Inst. 94, 1576-1578 (2002).
51. Qu Y, Adam BL, Yasui Y et al. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin. Chem. 48, 1835-1843 (2002).
52. Cazares LH, Adam BL, Ward MD et al. Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. Clin. Cancer Res. 8, 2541-2552 (2002).
53. Wellmann A, Wollscheid V, Lu H et al. Analysis of microdissected prostate tissue with ProteinChip arrays - a way to new insights into carcinogenesis and to diagnostic tools. Int. J. Mol. Med. 9, 341-347 (2002).
54. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin. Chem. 48, 1296-1304 (2002).
55. Becker S, Cazares LH, Watson P et al. Surfaced-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast cancer. Ann. Surg. Oncol. 11, 907-914 (2004).
56. Pusztai L, Gregory BW, Baggerly KA et al. Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer 100, 1814-1822 (2004).
57. Mathelin C, Cromer A, Wendling C, Tomasetto C, Rio MC. Serum biomarkers for detection of breast cancers: a prospective study. Breast Cancer Res. Treat. 1-8 (2005).
58. Li J, Orlandi R, White CN et al. Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin. Chem. 51, 2229-2235 (2005).
59. Goncalves A, Esterni B, Bertucci F et al. Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy. Oncogene 26, 26 (2005).
60. Paweletz CP, Trock B, Pennanen M et al. Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis. Markers 17, 301-307 (2001).
61. Sauter ER, Shan S, Hewett JE, Speckman P, Du Bois GC. Proteomic analysis of nipple aspirate fluid using SELDI-TOF-MS. Int J. Cancer 17, 17 (2004).
62. Kuerer HM, Coombes KR, Chen JN et al. Association between ductal fluid proteomic expression profiles and the presence of lymph node metastases in women with breast cancer. Surgery 136, 1061-1069 (2004).
63. Li J, Zhao J, Yu X et al. Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid. Clin. Cancer Res. 11, 8312-8320 (2005).
64. Ricolleau G, Charbonnel C, Lode L et al. Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors. Proteomics 6(6), 1963-1975 (2006).
65. Koopmann J, Zhang Z, White N et al. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin. Cancer Res. 10, 860-868 (2004).
66. Yu Y, Chen S, Wang LS et al. Prediction of pancreatic cancer by serum biomarkers using surface-enhanced laser desorption/ionization-based decision tree classification. Oncology 68, 79-86 (2005).
67. Zhukov TA, Johanson RA, Cantor AB, Clark RA, Tockman MS. Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry. Lung Cancer 40, 267-279 (2003).
68. Xiao X, Liu D, Tang Y et al. Development of proteomic patterns for detecting lung cancer. Dis. Markers 19, 33-39 (2003).
69. Yang SY, Xiao XY, Zhang WG et al. Application of serum SELDI proteomic patterns in diagnosis of lung cancer. BMC Cancer 5, 83 (2005).
70. Rogers MA, Clarke P, Noble J et al. Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Cancer Res. 63, 6971-6983 (2003).
71. Won Y, Song HJ, Kang TW, Kim JJ, Han BD, Lee SW. Pattern analysis of serum proteome distinguishes renal cell carcinoma from other urologic diseases and healthy persons. Proteomics 3, 2310-2316 (2003).
72. Soltys SG, Le QT, Shi G, Tibshirani R, Giaccia AJ, Koong AC. The use of plasma surface-enhanced laser desorption/ionization time-of-flight mass spectrometry proteomic patterns for detection of head and neck squamous cell cancers. Clin. Cancer Res. 10, 4806-4812 (2004).
73. Wadsworth JT, Somers KD, Stack BC Jr et al. Identification of patients with head and neck cancer using serum protein profiles. Arch. Otolaryngol. Head Neck Surg. 130, 98-104 (2004).
74. Melle C, Ernst G, Schimmel B et al. Biomarker discovery and identification in laser microdissected head and neck squamous cell carcinoma with ProteinChip® technology, two-dimensional gel electrophoresis, tandem mass spectrometry, and immunohistochemistry. Mol. Cell. Proteomics 2, 443-452 (2003).
75. Melle C, Kaufmann R, Hommann M et al. Proteomic profiling in microdissected hepatocellular carcinoma tissue using ProteinChip technology. Int. J. Oncol. 24, 885-891 (2004).
76. Wilson LL, Tran L, Morton DL, Hoon DS. Detection of differentially expressed proteins in early-stage melanoma patients using SELDI-TOF mass spectrometry. Ann. NY Acad. Sci. 1022, 317-322 (2004).
77. Tolson JP, Flad T, Gnau V et al. Differential detection of S100A8 in transitional cell carcinoma of the bladder by pair wise tissue proteomic and immunohistochemical analysis. Proteomics 6, 697-708 (2006). Original application of the complementary uses of SELDI-TOF and Clinprot for the profiling and identification of markers.
78. He QY, Zhu R, Ren Y, Tam PK, Chiu JF. Serological protein profiling of neuroblastoma by ProteinChip SELDI-TOF technology. J. Cell Biochem. 95, 165-172 (2005).
79. Krieg RC, Fogt F, Braunschweig T, Herrmann PC, Wollscheidt V, Wellmann A. ProteinChip array analysis of microdissected colorectal carcinoma and associated tumor stroma shows specific protein bands in the 3.4 to 3.6 kDa range. Anticancer Res. 24, 1791-1796 (2004).
80. Melle C, Ernst G, Schimmel B et al. Different expression of calgizzarin (S100A11) in normal colonic epithelium, adenoma and colorectal carcinoma. Int. J. Oncol. 28, 195-200 (2006).
81. Shiwa M, Nishimura Y, Wakatabe R et al. Rapid discovery and identification of a tissue-specific tumor biomarker from 39 human cancer cell lines using the SELDI ProteinChip platform. Biochem. Biophys. Res. Commun. 309, 18-25 (2003).
82. Chen YD, Zheng S, Yu JK, Hu X. Artificial neural networks analysis of surface-enhanced laser desorption/ionization mass spectra of serum protein pattern distinguishes colorectal cancer from healthy population. Clin. Cancer Res. 10, 8380-8385 (2004).
83. de Noo ME, Mertens BJ, Ozalp A et al. Detection of colorectal cancer using MALDI-TOF serum protein profiling. Eur. J. Cancer 5, 5 (2006).
84. Melle C, Ernst G, Schimmel B et al. Characterization of pepsinogen C as a potential biomarker for gastric cancer using a histo-proteomic approach. J. Proteome Res. 4, 1799-1804 (2005).
85. Qian HG, Shen J, Ma H et al. Preliminary study on proteomics of gastric carcinoma and its clinical significance. World J. Gastroenterol. 11, 6249-6253 (2005).
86. Wong YF, Cheung TH, Lo KW et al. Protein profiling of cervical cancer by protein-biochips: proteomic scoring to discriminate cervical cancer from normal cervix. Cancer Lett. 211, 227-234 (2004).